ABCL
AbCellera Biologics Inc.
Company Overview
| Mkt Cap | $1.08B | Price | $3.47 |
| Volume | 2.63M | Change | +1.76% |
| P/E Ratio | -- | Open | $3.42 |
| Revenue | -- | Prev Close | $3.41 |
| Net Income | -- | 52W Range | $1.89 - $6.52 |
| Div Yield | N/A | Target | $9.14 |
| Overall | 9 | Value | -- |
| Quality | -- | Technical | 9 |
No chart data available
About AbCellera Biologics Inc.
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Latest News
AbCellera Appoints Dr. Stephen Quake to Board
Analysts Are Bullish on Top Healthcare Stocks: CytomX Therapeutics (CTMX), AbCellera Biologics (ABCL)
AbCellera’s ABCL635 Study: A Promising Step for Menopause Treatment
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ABCL | $3.47 | +1.8% | 2.63M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get AbCellera Biologics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW